755039-52-2

Basic information

• Product Name: Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)-
• Synonyms: Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)-;(R)-Methyl 2-(cyclopentylaMino)butanoate;methyl 2- mmvvm q butanoate;methyl (R)-2-(cyclopentylamino)butanoate
• CAS NO: 755039-52-2
• Molecular Formula: C₁₀H₁₉NO₂
• Molecular Weight: 185.26
• Product Categories: API intermediates
• Mol File: 755039-52-2.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)-(755039-52-2)
• EPA Substance Registry System: Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)-(755039-52-2)

Safety Data

• Hazardous Substances Data: 755039-52-2(Hazardous Substances Data)

Usage

General Description

Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)- is a chemical compound with the molecular formula C10H19NO2. It is also known as (R)-2-(Cyclopentylamino)butyric acid methyl ester and is a derivative of butanoic acid. Butanoic acid, 2-(cyclopentylamino)-, methyl ester, (2R)- is primarily used in the pharmaceutical industry and is known for its potential use in the treatment of neurological disorders and cognitive enhancement. It acts as a selective agonist for the GABAB receptor, which plays a role in controlling neurotransmitter release and synaptic transmission in the brain. Additionally, it has potential applications in the treatment of mood disorders and anxiety, and has been the subject of research for its potential use in drug development.

Upstream product

• 74645-03-7 (R)-2-Aminobuttersaeure-methylester 
• 120-92-3 cyclopentanone 
• 85774-09-0 (R)-2-aminobutyric acid methyl ester hydrochloride 

Downstream Products

• 755039-53-3 (R)-methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)-amino)butanoate 
• 755039-54-4 (R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-one 
• 755039-55-5 (R)-2-chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one 
• 755039-56-6 (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzoic acid 
• 1344728-02-4 (R)-N-(2-aminoethyl)-4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide 
• 755038-02-9 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide 
• 1021853-34-8 1-tert-butyl 4-[(4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzoyl)amino]piperidine-1-carboxylate 
• 1021853-33-7 4-{[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxy-N-piperidin-4-ylbenzamide 

Relevant articles and documents

Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a sulfonyl moiety as potent dual inhibitors of PLK1 and BRD4

The simultaneous inhibition of PLK1 and BRD4 by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Herein, two series of novel pteridinone derivatives possessing a sulfonyl moiety were designed, synthesized and evaluated for their biological activity. Most compounds exhibited moderate to excellent cytotoxic activity against HCT116, PC3 and BT474 cell lines. Among them, the most promising compound B2 showed high antiproliferative effects on the three cell lines with IC50 values of 0.30 μM, 1.82 μM and 1.69 μM, respectively. In the enzymatic assay, B2 was identified as a potent PLK1 and BRD4 dual inhibitor (PLK1 IC50 = 6.3 nM, BRD4 IC50 = 179 nM). Further explorations in bioactivity were conducted to clarify the anticancer mechanism of compound B2. The results showed that compound B2 obviously inhibited the proliferation of HCT116 cell lines, induced a great decrease in the mitochondrial membrane potential leading to apoptosis of HCT116 cells and arrested the G2 phase of HCT116 cells.

Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer

Targeting poly(ADP-ribose) polymerase1/2 (PARP1/2) is a promising strategy for the treatment of pancreatic cancer with breast cancer susceptibility gene (BRCA) mutation. Inducing the deficiency of homologous recombination (HR) repair is an effective way t

Pyrimidinyl-piperazine-1, 2, 4-triazole derivative, and preparation method and application thereof

The invention discloses a pyrimidinyl-piperazine-1, 2, 4-triazole derivative, and a preparation method and application thereof. The structural formula of the compound is shown in the specification. Inthe formula, R1 is a chain or cyclic aliphatic hydrocar